<DOC>
	<DOC>NCT00375323</DOC>
	<brief_summary>The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.</brief_summary>
	<brief_title>Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Adult patients with hemophilia A and current antibodies to factor VIII Lifethreatening hemorrhage Severe liver failure Any other severe comorbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury) Exposure to other haemostatic drugs during the previous 7 days Hypersensitivity to hamster, mouse or bovine proteins Known or suspected allergy to NovoSevenïƒ’ or any of its components</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>factor VIII inhibitor</keyword>
</DOC>